Breaking

The Assad regime ruled Syria for 50 years. Here’s how it fell in less than two weeks
Haiti gang massacre leaves over 180 dead after Voodoo accusations, say UN and rights groups
Rebel group claims to have taken control of Myanmar’s border with Bangladesh in grinding civil war
CNN goes inside Syria’s ‘slaughterhouse’ prison as desperate families look for missing loved ones
A mass animal sacrifice festival is underway in Nepal. Activists say it needs to stop
Nauru agrees to give Australia veto rights overpacts with third nations including China
Brazil’s Lula undergoes brain surgery, stable in ICU
Netanyahu takes the stand in his corruption trial for the first time

Business
World
Politics
Investing
Search for:

Investing

Completion of preclinical data package for RAD 402

December 10, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced Completion of preclinical data package for RAD 402

Download the PDF here.

This post appeared first on investingnews.com

Related Posts

Zero Candida Receives South African Patent for its ZC- 01 device

December 10, 2024

Syntheia Commences SOC 2 Type I Certification, Reinforcing Commitment to Data Privacy and Security

December 10, 2024

Capital Raising and QSM Completion Update

December 10, 2024

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (1,081)
- Investing (2,227)
- Politics (3,137)
- World (3,066)

Disclaimer: RiskManagementMasters.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2024 RiskManagementMasters.com | All Rights Reserved

Top

Business
World
Politics
Investing

Type above and press Enter to search. Press Esc to cancel.